Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.
Opinion|Podcasts|July 31, 2024
Novel Treatments and Diagnostics for Dry Eye
Listen
0:00 / 0:00
Experts discuss strategies for making dry eye care an appealing practice option for optometry students and supporting their success in this specialized field.
Advertisement
Timecodes:
0:55 Treatment Advanced
5:00 Treating Demodex
13:40 Semifluorinated Alkanes
16:15 Treatment Selection
22:10 New Research Targets
28:50 AI in Diagnostics
Advertisement
Related to this article
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
Advances in Treating High-Impact Psoriasis from EADV 2026
3
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines to Include HYPERION Data
4
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
5